Subtype
Rectal Neoplasm
CI-CAN-00006564Explore in graph →
Non-malignant433 active trials1 approved drugs5 evidence items
Loading cancer entity…
Subtype
CI-CAN-00006564Explore in graph →
Clinical trials
1,772 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07209787 | SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak | recruiting | Phase 4 | 966 | Beijing Chao Yang HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT05038254 | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | active not recruiting | N/A | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651007 | Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR | not yet recruiting | Phase 2 | 29 | Wang XinOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07651553 | Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision(TaLaR03) | recruiting | N/A | 216 | Sun Yat-sen UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05943210 | The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer(ROBIN) | recruiting | N/A | 25 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07646639 | Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC(PRIDE-02) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01148056 | Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer | terminated | N/A | 2 | Massachusetts General HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07011576 | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)(FRUITFUL) | recruiting | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07645118 | Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer(IMPERIA) | not yet recruiting | Phase 2 | 10 | Dr. Te VuongOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04804956 | Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer(BIORECTUM) | recruiting | — | 100 | University Hospital of Girona Dr. Josep TruetaNETWORK | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer(REACT) | recruiting | Phase 3 | 103 | Erasmus Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07292285 | The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.(SNOWW) | withdrawn | — | 0 | University of Colorado, DenverOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07306390 | Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)(DIAMOND) | not yet recruiting | — | 1,200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07467434 | FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases(SYNCHRONOX) | recruiting | — | 550 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05245786 | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | active not recruiting | Early Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05331040 | Radiomics in Rectal Cancer | withdrawn | — | 0 | NHS GrampianOTHER_GOV | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03781323 | Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 12 | University of RochesterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07281157 | Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07612748 | Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms | recruiting | N/A | 483 | Jilin UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05007015 | Transanal Irrigation for the Management of LARS(TAI-LARS) | active not recruiting | N/A | 66 | Jewish General HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06637462 | A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer | recruiting | N/A | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619768 | Self Regulation Hypnotic Intervention for Pain and Anxiety During Rectal Brachytherapy | completed | N/A | 52 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07622017 | KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer(K-BOOST) | not yet recruiting | Phase 2 | 24 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07616297 | Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients(REBOOT) | recruiting | N/A | 25 | Claudia SchuurhuizenOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02403505 | Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer(CEA+RC-BCG) | active not recruiting | Phase 1 | 20 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT05723562 | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer(AZUR-1) | active not recruiting | Phase 2 | 154 | GlaxoSmithKlineINDUSTRY | 10 | May 26, 2026 | clinicaltrials |
| NCT07176182 | Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression | recruiting | Phase 2 | 236 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07605611 | Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection(SC-Stoma) | recruiting | N/A | 72 | Tongji HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03548961 | Organ Preservation in Early Rectal Cancer Patients | active not recruiting | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04503694 | Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer(REGINA) | active not recruiting | Phase 2 | 72 | Jules Bordet InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03594630 | Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer | recruiting | Early Phase 1 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT07594925 | Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07595107 | Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer | not yet recruiting | — | 180 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07596732 | Statewide Unified Network for Remote Intervention of Strength and Exercise(SUNRISE) | not yet recruiting | N/A | 120 | AdventHealth Translational Research InstituteOTHER | 0 | May 19, 2026 | clinicaltrials |
| NCT07581626 | Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT01408407 | Alkagin Paste in the Prevention of Radiation Dermatitis | terminated | Phase 2 | 2 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02514278 | Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy(GRECCAR12) | completed | Phase 3 | 218 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05877352 | Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial(ELECTRA) | active not recruiting | N/A | 31 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05672524 | A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | recruiting | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06123156 | Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer(RECTIL) | recruiting | Phase 3 | 188 | University Hospital, RouenOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07580027 | Preoperative, Adaptive Radiotherapy Concomitant to Chemotherapy for Rectal Adenocarcinoma (Adaptive Rectal Cancer Trial 02) | not yet recruiting | N/A | 33 | IRCCS San RaffaeleOTHER | 1 | May 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials